Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

pharmachim ab - merkaptopurinmonohydrat - tablett - 50 mg - laktosmonohydrat hjälpämne; merkaptopurinmonohydrat 50 mg aktiv substans - merkaptopurin

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

orifarm ab - merkaptopurinmonohydrat - tablett - 50 mg - merkaptopurinmonohydrat 50 mg aktiv substans; laktosmonohydrat hjälpämne - merkaptopurin

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

orifarm ab - merkaptopurinmonohydrat - tablett - 50 mg - merkaptopurinmonohydrat 50 mg aktiv substans; laktosmonohydrat hjälpämne - merkaptopurin

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - merkaptopurinmonohydrat - tablett - 50 mg - laktosmonohydrat hjälpämne; merkaptopurinmonohydrat 50 mg aktiv substans - merkaptopurin

Европска Унија - Шведски - EMA (European Medicines Agency)

albireo - odevixibat - cholestasis, intrahepatic - gall- och leverterapi - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 och 5.

Европска Унија - Шведски - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 och 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Европска Унија - Шведски - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - multipel skleros, skovvis förlöpande - immunsuppressiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

mylan s.a.s. - risperidon - munsönderfallande tablett - 3 mg - mannitol hjälpämne; aspartam hjälpämne; risperidon 3 mg aktiv substans - risperidon

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

mylan s.a.s. - risperidon - munsönderfallande tablett - 4 mg - mannitol hjälpämne; aspartam hjälpämne; risperidon 4 mg aktiv substans - risperidon

Европска Унија - Шведски - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multipel skleros - selektiva immunsuppressiva medel - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 och 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.